EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Assessment of pharmacokinetics and tolerability following single‐dose administration of molnupiravir in participants with hepatic or renal impairment

Kelly E Duncan iD, Russ P Carstens iD, Kristin L Butterfield, Yoon Jin, Laura R Inbody, Andrea K Schaeffer, Catherine Z Matthews, Tian Zhao, Shruti Patel, Brian M Maas iD, Mickie H Cheng iD, S Aubrey Stoch iD

Clinical and Translational Science · 2024

DOI: 10.1111/cts.70073 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Kelly E Duncan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Cytidine, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Individuals with chronic liver or kidney disease are at increased risk of severe COVID‐19. Molnupiravir is an orally administered antiviral authorized for the treatment of mild‐to‐moderate COVID‐19 in adults at risk of progression to severe disease. Two nonrandomized, open‐label, single‐dose, multicenter, phase 1 trials were conducted to investigate the effects of hepatic and renal impairment on the tolerability and pharmacokinetics of molnupiravir (800 mg) and its metabolite β‐D‐N4‐hydroxycytidine (NHC; NCT05386589/NCT05386758). The impact of renal impairment on urinary excretion of NHC was also assessed. The 90% CI for the geometric mean ratio of the plasma NHC area under the concentration–time curve (AUC) from zero to infinity was

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytidineAntiviral AgentsCOVID-19 Drug TreatmentHumansMaleFemaleMiddle AgedAdultAgedHydroxylaminesSARS-CoV-2Renal InsufficiencyUridineArea Under CurveAdministration, OralCOVID-19

Substanzen

molnupiravirCytidineAntiviral AgentsHydroxylaminesN(4)-hydroxycytidineUridine

Autor:innen und Institutionen

  • Merck & Co., Inc., Rahway, New Jersey, USA.

ORCID-Profile: Kelly E Duncan, Russ P Carstens, Brian M Maas, Mickie H Cheng, S Aubrey Stoch

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Zitieren

APA

Duncan, K. E., Carstens, R. P., Butterfield, K. L., Jin, Y., Inbody, L. R., Schaeffer, A. K., Matthews, C. Z., Zhao, T., Patel, S., Maas, B. M., Cheng, M. H., & Stoch, S. A. (2024). Assessment of pharmacokinetics and tolerability following single‐dose administration of molnupiravir in participants with hepatic or renal impairment. Clinical and Translational Science. https://doi.org/10.1111/cts.70073

Vancouver

Duncan KE, Carstens RP, Butterfield KL, Jin Y, Inbody LR, Schaeffer AK, et al. Assessment of pharmacokinetics and tolerability following single‐dose administration of molnupiravir in participants with hepatic or renal impairment. Clinical and Translational Science. 2024. doi:10.1111/cts.70073

BibTeX
@article{Duncan2024,
  author = {Duncan, Kelly E and Carstens, Russ P and Butterfield, Kristin L and Jin, Yoon and Inbody, Laura R and Schaeffer, Andrea K and Matthews, Catherine Z and Zhao, Tian and Patel, Shruti and Maas, Brian M and Cheng, Mickie H and Stoch, S Aubrey},
  title = {Assessment of pharmacokinetics and tolerability following single‐dose administration of molnupiravir in participants with hepatic or renal impairment},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.70073}
}
Kostenlos starten →